{"id":246314,"date":"2026-11-01T10:17:37","date_gmt":"2026-11-01T16:17:37","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/11\/efficacy-and-safety-of-garetosmab-an-activin-a-blocking-antibody-in-fibrodysplasia-ossificans-progressiva-optima-a-randomised-double-blind-placebo-controlled-phase-3-trial"},"modified":"2026-11-01T10:17:37","modified_gmt":"2026-11-01T16:17:37","slug":"efficacy-and-safety-of-garetosmab-an-activin-a-blocking-antibody-in-fibrodysplasia-ossificans-progressiva-optima-a-randomised-double-blind-placebo-controlled-phase-3-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/11\/efficacy-and-safety-of-garetosmab-an-activin-a-blocking-antibody-in-fibrodysplasia-ossificans-progressiva-optima-a-randomised-double-blind-placebo-controlled-phase-3-trial","title":{"rendered":"Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial"},"content":{"rendered":"\n<p>Garetosmab substantially reduced the number of new heterotopic bone lesions, providing robust evidence of its potential to be an efficacious and generally well tolerated disease-modifying therapy for FOP.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Garetosmab substantially reduced the number of new heterotopic bone lesions, providing robust evidence of its potential to be an efficacious and generally well tolerated disease-modifying therapy for FOP.<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-246314","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/246314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=246314"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/246314\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=246314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=246314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=246314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}